

The Board of Pharmacy has received notice of the following product withdrawal. The Board strongly encourages pharmacies to immediately review their quality assurance and recall policies and procedures to determine if any corrective action is required.

**Subject: Immune Globulin Intravenous (Human)
Privigen® 10%**

On December 30, 2021, CSL Behring instituted a withdrawal of one lot of PRIVIGEN (Lot #P100356115) at the hospital/pharmacy level due to an increased frequency of reports of hypersensitivity reactions during or after administration. This update is to announce three (3) additional Privigen lots (Lot #P100366291, Lot #P100371288, Lot #P100287718) are now also being withdrawn. Hypersensitivity reactions are a known risk with Intravenous Immune Globulin (IVIG) products.

The tables below indicate the impacted lots of PRIVIGEN that were shipped from CSL Behring between November 16, 2021, and December 16, 2021:

Privigen® 10% (20g/200mL)

NDC: 44206-0438-20

LOT	EXPIRY DATE
P100356115	5-JUL-2024

Privigen® 10% (40g/400mL)

NDC: 44206-0439-40

LOT	EXPIRY DATE
P100366291	19-AUG-2024
P100371288	20-AUG-2024

Privigen® 10% (5g/50mL)

NDC: 44206-0436-05

LOT	EXPIRY DATE
P100287718	15-NOV-2023